Key result
AMI reperfusion therapy evolves from early studies to modern refinements including ambulance-based therapy and PCI.
This historical review traces the development of reperfusion therapy for acute myocardial infarction from its inception to modern refinements like PCI and adjunctive pharmacotherapy.
Historical context on AMI reperfusion informs practice; leaves open optimal future refinements in delivery and adjuncts.
Reperfusion therapy for acute myocardial infarction is a milestone achievement in 20th century cardiology. This article tracks this therapy from the discovery that coronary thrombosis is the cause of myocardial infarction, through the pre-clinical era when studies in dogs demonstrated the benefit of early reperfusion. Then came early clinical observations in the feasibility of coronary thrombolysis in patients, followed by the early placebo-controlled megatrials (GISSI-I and ISIS-2), which showed a substantial mortality benefit. During the past decade there have been important refinements using ambulance-based therapy, new bolus thrombolytics, adjunctive glycoprotein inhibitors and percutaneous coronary intervention.
No takes yet. Share an insight, caveat, or question.
Eugene Braunwald (2002) conducted a review in acute myocardial infarction. Reperfusion therapy was evaluated. Reperfusion therapy for acute myocardial infarction has evolved from early pre-clinical studies to modern refinements including ambulance-based therapy, new thrombolytics, and PCI.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: